Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2015 (2015), Article ID 165105, 9 pages
http://dx.doi.org/10.1155/2015/165105
Review Article

Switching the Sphingolipid Rheostat in the Treatment of Diabetes and Cancer Comorbidity from a Problem to an Advantage

1The University of Queensland, The University of Queensland Diamantina Institute, Translational Research Institute, Brisbane, QLD, Australia
2The Centenary Institute, Newtown, NSW, Australia
3Discipline of Dermatology, University of Sydney, Camperdown, NSW, Australia
4School of Medical and Molecular Biosciences, University of Technology Sydney, Ultimo, NSW 2007, Australia
5Sydney Medical School, University of Sydney, Camperdown, NSW 2050, Australia

Received 17 July 2014; Accepted 16 October 2014

Academic Editor: Anandwardhan Hardikar

Copyright © 2015 Nikolas K. Haass et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

How to Cite this Article

Nikolas K. Haass, Najah Nassif, and Eileen M. McGowan, “Switching the Sphingolipid Rheostat in the Treatment of Diabetes and Cancer Comorbidity from a Problem to an Advantage,” BioMed Research International, vol. 2015, Article ID 165105, 9 pages, 2015. doi:10.1155/2015/165105